Lennox Gastaut Syndrome

Danish pharma Lundbeck vastly increased its offer to buy Longboard Pharmaceuticals over six months as other parties came to the dealmaking table, a new SEC filing shows. Lundbeck initially proposed $29 per share $LBPH on April 19 to buy the Phase 3 neurology biotech. By Oct. 14, when the $2.6 billion cash deal was announced, it had raised its offer to $60, according to an SEC filing on Wednesday morning. At the time, Lundbeck CEO Charl van Zyl told Endpoints News the deal was within the “benchmark premium” for companies with assets in Phase 3. “We believe we have fundamentally not overpaid for this asset,” he said in the interview. Longboard said last month that its 5-HT2C superagonist known as bexicaserin had entered Phase 3 for Dravet syndrome and has broader plans to test the treatment in other epileptic encephalopathies like Lennox-Gastaut syndrome. Lundbeck had been intrigued by the Phase 1b/2a data that Longboard shared on Jan. 2 for patients who experience seizures associated with developmental and epileptic encephalopathies. That data skyrocketed Longboard’s stock price from $6.03 on Dec. 29 to $25.10 on Jan. 2. Shortly after the data release, Lundbeck representatives met with Longboard CEO Kevin Lind at the annual JP Morgan Healthcare Conference. Lundbeck would go on to increasingly raise its offer from $29.00 to $34.50, then $54.00 and $59.00. Lind wanted $62.00 a share, but they eventually settled on $60.00. During the process, Longboard had also talked with other undisclosed companies, codenamed Parties A, B, C and D, according to another SEC filing on Wednesday. Party A had submitted a few offers, including one as high as $60.00 on Sept. 27. But on Oct. 2, Party A told Longboard it was no longer interested because of “various perceived risks,” according to the SEC document.

SAN DIEGO, Oct. 17, 2024 /PRNewswire/ -- Tickets are now available for the December 5, 2024 showing of It's All Your Fault, Tyler Price!, a new musical created by Emmy-Winning Composer Ben Decter (Lucifer) and Tony-Nominated Director Kristin Hanggi (Rock of Ages), which highlights the hardships and stigma of living with epilepsy and Lennox-Gastaut Syndrome (LGS). Epilepsy affects 50 million people worldwide and is the fourth most common neurological disease after migraines, stroke, and Alzheimer's Disease. Despite its prevalence and the fact that 1 in 26 Americans will develop epilepsy in their lifetime, awareness and research funding lag behind. In some cases, epilepsy can be controlled with currently available therapies, but this is not the case for Lennox-Gastaut Syndrome (LGS), a rare, severe, life-threatening epilepsy syndrome that develops in children and leads to lifelong disability. Approximately 1 million children and adults worldwide have LGS, yet no broadly effective treatments exist. The LGS Foundation has partnered with Decter and Hanggi to raise awareness and shine a light on what it is like to live with these disorders. "When my family was in crisis—my little girl, diagnosed with Lennox-Gastaut Syndrome, was having 100 seizures a day and we felt so isolated—I never imagined a musical would grow out of it. Writing these songs helped my family have difficult conversations and come together," says Decter in a statement. "It's All Your Fault, Tyler Price! is a fun, irreverent look at a family going through a really hard time—that everyone can relate to." "This musical is a true passion project for us. It's about dealing with struggles in our families and how challenging it is to be seen by those closest to us," adds Hanggi. "Through art, our characters learn to explore uncomfortable feelings—things that can be difficult to share or admit. We can't wait for Los Angeles—where I've gotten the opportunity to launch other new musicals—to see our show!" "Raising awareness of epilepsy and LGS has never been more critical," shares Dr. Tracy Dixon-Salazar, Executive Director of the LGS Foundation and mother to an adult daughter who has LGS. "For far too long have these conditions been kept in the shadows and not talked about. We are thrilled to partner on this project and help educate the community in a fun and approachable way. We hope folks will come out and enjoy the show and learn about epilepsy and LGS in the process." About the LGS Foundation The LGS Foundation is a nonprofit organization dedicated to improving the lives of individuals impacted by LGS through advancing research, awareness, education, and family support. To learn more, visit . SOURCE Lennox-Gastaut Syndrome (LGS) Foundation WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Lundbeck and Longboard Pharmaceuticals have announced an agreement for the Danish pharmaceutical company to acquire all outstanding shares of Longboard, in a transaction valued at $2.6 billion in equity value. The transaction is expected to close by the end of the year. The deal will give Lundbeck ownership over Longboard’s pipeline of drug candidates for neurological and rare diseases. The lead asset, bexicaserin, is in late-stage development for the treatment of developmental and epileptic encephalopathies (DEEs), a group of severe epilepsies with onset in early childhood that affect over 220,000 people in the US alone. “This transformative transaction will become a cornerstone in Lundbeck’s neuro-rare franchise, with a potential to drive growth into the next decade. Bexicaserin addresses a critical unmet need for patients suffering from rare and severe epilepsies, for which there are very few good treatment options available," said Charl van Zyl, President and CEO of Lundbeck. The acquisition of Longboard will expand Lundbeck’s drug development pipeline, which focuses exclusively on therapeutic products for brain diseases, ranging from migraines to Parkinson’s. In particular, Longboard’s small molecule drug candidates are designed to selectively target G protein-coupled receptors (GPCRs), the most successful class of druggable targets in the human genome. In September this year, Longboard initiated a phase 3 clinical trial evaluating its lead asset, bexicaserin, for the treatment of seizures associated with Dravet syndrome. googletag.cmd.push(function () { googletag.display('text-ad1'); }); Cleveland Clinic describes Dravet syndrome as a rare type of epilepsy. Seizures usually start in the first year of a child’s life. In addition to frequent and varied seizures, children will experience lags in mental and physical development, with the possibility of many other symptoms. Medications help reduce the number and severity of symptoms. Bexicaserin is an oral drug candidate with a next-generation super-agonist mechanism that targets 5-hydroxytryptamine (5-HT) 2C receptors, a type of serotonin receptors that are linked to epilepsy. The drug candidate has a differentiated mechanism of action that targets 5-HT 2C ​ specifically, without impacting other 5-HT receptor subtypes such as 5-HT 2A ​ and 5-HT 2B ​. In preclinical and clinical studies, Bexicaserin has shown anti-seizure effects, with a best-in-class profile in Dravet syndrome, Lennox-Gastaut syndrome and other DEEs. The drug has blockbuster potential in this area of high unmet need, with global peak sales expected to be as high as $2 billion. “Longboard was founded to transform the lives of people living with devastating neurological conditions,” stated Kevin R. Lind, President and Chief Executive Officer of Longboard. “Lundbeck’s remarkable capabilities will accelerate our vision to provide increased equity and access for underserved DEE patients with significant unmet medical needs.”